Institut Curie’s SIRIC program re-endorsed for 2018 – 2022
Institut Curie's SIRIC program is among the 8 projects labelled SIRIC in 2018 by the French National Cancer Institute in partnership with INSERM and DGOS.
This label recognizes the quality of work carried out by all of the parties involved in the construction of the project but also the excellence of the results obtained by clinicians and researchers in the frame of the 1st SIRIC endorsement (2011-2017).
A program combatting resistance to anti-cancer therapies
The SIRIC-Curie 2018-2022 program will be focused on 3 pathologies for which Institut Curie is a reference center and for which therapeutic impasses remain:
- Breast cancers
coordinated by Anne Vincent-Salomon and Philip Poortmans
- Pediatric cancers
coordinated by Gudrun Schleiermacher and Olivier Delattre
- Uveal melanoma
coordinated by Sophie Piperno-Neumann and Marc-Henri Stern
This program, aiming to combat treatment-resistant diseases, will be based on results obtained during the 1st SIRIC endorsement and will integrate new themes (clonality and cell plasticity, impact of metabolism, integration of different omics aspects, sequencing and therapy combination...).
It will be firmly built with and for the patients through the participation of a committee of patient representatives at all levels of the project (governance, research program and dissemination).
SIRIC-Curie is gaining momentum to reach a stronger level of integration between research and care and thus improving the response to patients’ needs in the context of therapeutic resistance.